title: [Preclinical and clinical trials of the new tuberculosis drug perchlozon].
abstract: The paper sets forth the stages of design and introduction of the new Russian tuberculosis (TB) drug perchlozon registered in the Russian Federation in 2012. Based on the results of Phases I-III clinical trials, the authors evaluate the efficacy and safety of the agent and consider the adverse effects of its treatment for respiratory TB. The use of perchlozon as a component of combination therapy versus standard chemotherapy regimens significantly reduces abacillation time in pulmonary TB caused by its drug-resistant pathogen. In terms of the higher prevalence of TB induced by its pathogen resistant to many drugs (with multiple and broad-spectrum drug resistance), perchlozon is an essential drug that has antituberculous activity mainly against multidrug-resistant Mycobacterium tuberculosis strains and gives patients with the severest and epidemiologically poor form of TB the chance to recover.
authors.affiliation: Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia, Saint Petersburg, Russia; Saint Petersburg State University, Saint Petersburg, Russia.
authors.forename: P K
authors.initials: PK
authors.lastname: Yablonskiy
authors.affiliation: Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia, Saint Petersburg, Russia.
authors.forename: T I
authors.initials: TI
authors.lastname: Vinogradova
authors.affiliation: Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia, Saint Petersburg, Russia.
authors.forename: Yu N
authors.initials: YN
authors.lastname: Levashev
authors.affiliation: Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia, Saint Petersburg, Russia.
authors.forename: M V
authors.initials: MV
authors.lastname: Pavlova
authors.affiliation: Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia, Saint Petersburg, Russia.
authors.forename: E K
authors.initials: EK
authors.lastname: Zilber
authors.affiliation: Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia, Saint Petersburg, Russia.
authors.forename: A A
authors.initials: AA
authors.lastname: Starshinova
authors.affiliation: Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia, Saint Petersburg, Russia.
authors.forename: N V
authors.initials: NV
authors.lastname: Sapozhnikova
authors.affiliation: Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia, Saint Petersburg, Russia.
authors.forename: I V
authors.initials: IV
authors.lastname: Chernokhaeva
authors.affiliation: Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia, Saint Petersburg, Russia; Saint Petersburg State University, Saint Petersburg, Russia.
authors.forename: L I
authors.initials: LI
authors.lastname: Archakova
authors.affiliation: Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia, Saint Petersburg, Russia.
authors.forename: N V
authors.initials: NV
authors.lastname: Zabolotnykh
authors.affiliation: Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia, Saint Petersburg, Russia.
authors.forename: M L
authors.initials: ML
authors.lastname: Vitovskaya
mesh_terms: D000995:Antitubercular Agents / Q000009:adverse effects / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D006801:Humans; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents